Literature DB >> 21831731

Effects of E2F1-cyclin E1-E2 circuit down regulation in hepatocellular carcinoma cells.

Rossella Farra1, Barbara Dapas, Gabriele Pozzato, Bruna Scaggiante, Francesco Agostini, Cristina Zennaro, Mario Grassi, Natalia Rosso, Carlo Giansante, Nicola Fiotti, Gabriele Grassi.   

Abstract

BACKGROUND: No effective therapy is available for hepatocellular carcinoma. To identify novel therapeutic strategies, we explored the effects of the depletion of E2F1, cyclin E1-E2 whose inter-relationships in hepatocellular carcinoma cell proliferation have never been defined.
METHODS: siRNA-mediated depletion of the targets was studied in the hepatocellular carcinoma cells HepG2, HuH7 and JHH6 characterized by high, medium and low hepatocyte differentiation grade, respectively; a model of normal human hepatocytes was also considered.
RESULTS: The depletion of each target mRNA reduced the levels of the other two mRNAs, thus demonstrating a close regulatory control, also confirmed by over-expression experiments. At the protein level, an exception to this trend was observed for cyclinE1 whose amount increased upon cyclin E2 (HepG2, HuH7, JHH6) and E2F1 (HepG2) depletion. In HepG2, reduced cyclinE1 proteolysis accounted for this observation. Additionally, cyclin E1-E2-E2F1 targeting decreased the levels of cyclin A2 mRNA and of the hyper-phosphorylated form of pRb thus leading to an S-phase cell decrease; migration was impaired as well. Finally, the model of human hepatocytes used was clearly less affected by target mRNAs depletion than hepatocellular carcinoma cells.
CONCLUSION: Our data provide novel mutual relationships amongst cyclin E1-E2-E2F1 and indicate their role in sustaining hepatocellular carcinoma cell proliferation/migration, validating the concept of an anti-cyclin E1-E2-E2F1 therapeutic approach for hepatocellular carcinoma. Copyright Â
© 2011 Editrice Gastroenterologica Italiana S.r.l. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21831731     DOI: 10.1016/j.dld.2011.07.007

Source DB:  PubMed          Journal:  Dig Liver Dis        ISSN: 1590-8658            Impact factor:   4.088


  17 in total

1.  Synergistic effects of AKAP95, Cyclin D1, Cyclin E1, and Cx43 in the development of rectal cancer.

Authors:  Fengjie Qi; Yangyang Yuan; Xuehong Zhi; Qian Huang; Yuexin Chen; Wenxin Zhuang; Dengcheng Zhang; Bogang Teng; Xiangyu Kong; Yongxing Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

Review 2.  Therapeutic potential of small interfering RNAs/micro interfering RNA in hepatocellular carcinoma.

Authors:  Rossella Farra; Mario Grassi; Gabriele Grassi; Barbara Dapas
Journal:  World J Gastroenterol       Date:  2015-08-14       Impact factor: 5.742

3.  The hnRNP RALY regulates transcription and cell proliferation by modulating the expression of specific factors including the proliferation marker E2F1.

Authors:  Nicola Cornella; Toma Tebaldi; Lisa Gasperini; Jarnail Singh; Richard A Padgett; Annalisa Rossi; Paolo Macchi
Journal:  J Biol Chem       Date:  2017-09-27       Impact factor: 5.157

4.  Angiopoietin-1 Upregulates Cancer Cell Motility in Colorectal Cancer Liver Metastases through Actin-Related Protein 2/3.

Authors:  Miran Rada; Audrey Kapelanski-Lamoureux; Migmar Tsamchoe; Stephanie Petrillo; Anthoula Lazaris; Peter Metrakos
Journal:  Cancers (Basel)       Date:  2022-05-21       Impact factor: 6.575

5.  Reversing multidrug-resistant by RNA interference through silencing MDR1 gene in human hepatocellular carcinoma cells subline Bel-7402/ADM.

Authors:  Long Sheng; Maoming Xiong; Cong Li; Xiangling Meng
Journal:  Pathol Oncol Res       Date:  2013-12-11       Impact factor: 3.201

6.  Bortezomib effect on E2F and cyclin family members in human hepatocellular carcinoma cell lines.

Authors:  Daniele Baiz; Barbara Dapas; Rossella Farra; Bruna Scaggiante; Gabriele Pozzato; Fabrizio Zanconati; Nicola Fiotti; Lara Consoloni; Sara Chiaretti; Gabriele Grassi
Journal:  World J Gastroenterol       Date:  2014-01-21       Impact factor: 5.742

7.  Combined Used of Rheology and LF-NMR for the Characterization of PVP-Alginates Gels Containing Liposomes.

Authors:  Giulia Fanesi; Michela Abrami; Francesca Zecchin; Irina Giassi; Elena Dal Ferro; Anja Boisen; Gabriele Grassi; Paolo Bertoncin; Mario Grassi; Paolo Marizza
Journal:  Pharm Res       Date:  2018-07-02       Impact factor: 4.200

8.  LncRNA SNHG6 promotes G1/S-phase transition in hepatocellular carcinoma by impairing miR-204-5p-mediated inhibition of E2F1.

Authors:  Kai Chen; Yifu Hou; Rui Liao; Youzan Li; Hongji Yang; Jun Gong
Journal:  Oncogene       Date:  2021-04-06       Impact factor: 9.867

9.  RNA-Seq profiling reveals novel hepatic gene expression pattern in aflatoxin B1 treated rats.

Authors:  B Alex Merrick; Dhiral P Phadke; Scott S Auerbach; Deepak Mav; Suzy M Stiegelmeyer; Ruchir R Shah; Raymond R Tice
Journal:  PLoS One       Date:  2013-04-22       Impact factor: 3.240

10.  A novel HMGA1-CCNE2-YAP axis regulates breast cancer aggressiveness.

Authors:  Silvia Pegoraro; Gloria Ros; Yari Ciani; Riccardo Sgarra; Silvano Piazza; Guidalberto Manfioletti
Journal:  Oncotarget       Date:  2015-08-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.